Flexus Biosciences

Immuno-oncology biotechnology company focused on developing small molecule inhibitors of IDO1 for cancer treatment. Acquired by Bristol-Myers Squibb in 2015 for $1.25 billion.

Location
San Carlos, California, USA
Founded
2013
Investors
1
Categories
biotech, therapeutics, immuno-oncology, acquired

Investors

NameLocationTypeStagesPortfolio
Kleiner PerkinsMenlo Park, California, USAgeneralist
seedseries-a+3
4